Cellular and plasmatic immune profile of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer: relevance of immunosuppressive factors
P. Rodrigues-Santos (Coimbra, Portugal), J. Almeida (Coimbra, Portugal), L. Sousa (Coimbra, Portugal), M. Santos-Rosa (Coimbra, Portugal), F. Barata (Coimbra, Portugal), A. Figueiredo (Coimbra, Portugal)
Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Rodrigues-Santos (Coimbra, Portugal), J. Almeida (Coimbra, Portugal), L. Sousa (Coimbra, Portugal), M. Santos-Rosa (Coimbra, Portugal), F. Barata (Coimbra, Portugal), A. Figueiredo (Coimbra, Portugal). Cellular and plasmatic immune profile of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer: relevance of immunosuppressive factors. 1918
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|